| Drug Name |
Canagliflozin |
| Drug ID |
BADD_D00344 |
| Description |
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label].
It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus [L5897], [FDA label].
Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897]. Cardiovascular disease is the most common cause of death in these patients [A177083]. |
| Indications and Usage |
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus [FDA label].
Another indication for canagliflozin is the prevention of major cardiovascular events (myocardial infarction, stroke, or death due to a cardiovascular cause) in patients with type 2 diabetes, as well as hospitalization for heart failure in patients with type 2 diabetes[L5897,[L8917].
In addition to the above, canagliflozin can be used to lower the risk of end-stage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus, diabetic nephropathy, and albuminuria.[L8917]
It is important to note that this drug is **not** indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis [FDA label]. |
| Marketing Status |
approved |
| ATC Code |
A10BK02 |
| DrugBank ID |
DB08907
|
| KEGG ID |
D09592
|
| MeSH ID |
D000068896
|
| PubChem ID |
24812758
|
| TTD Drug ID |
D08DFX
|
| NDC Product Code |
55111-978; 50923-1216; 50090-4364; 12578-615; 59651-065; 17314-575; 50090-5029; 50090-5033; 12578-611; 14445-017; 42385-735; 70966-0001; 17314-577; 50090-5034; 55154-1425; 50458-140; 50458-141; 55154-1426 |
| UNII |
0SAC974Z85
|
| Synonyms |
Canagliflozin | Invokana | Canagliflozin Hemihydrate | Canagliflozin, Anhydrous | 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973 |
